Detalles de la búsqueda
1.
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.
Support Care Cancer
; 32(5): 280, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38594320
2.
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Support Care Cancer
; 32(1): 53, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129530
3.
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Support Care Cancer
; 32(1): 45, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114821
4.
Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
Oncologist
; 26(3): 224-230, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098189
5.
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Oncologist
; 25(3): e589-e597, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162813
6.
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Future Oncol
; 15(20): 2371-2383, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31354046
7.
Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).
Support Care Cancer
; 26(7): 2353-2359, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29417293
8.
Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
Support Care Cancer
; 26(7): 2229-2238, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29392480
9.
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.
Support Care Cancer
; 25(5): 1661-1671, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28108820
10.
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 289-294, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27510316
11.
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
Support Care Cancer
; 25(1): 271-275, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501965
12.
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Oncologist
; 21(4): 494-502, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27000465
13.
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Curr Oncol Rep
; 18(6): 37, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27138015
14.
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Support Care Cancer
; 24(11): 4617-25, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27334131
15.
Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients.
Breast Cancer Res Treat
; 151(3): 679-86, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25981897
16.
The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis.
Acta Oncol
; 59(1): 96-100, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31552770
17.
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Future Oncol
; 11(18): 2541-51, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26289588
18.
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
Support Care Cancer
; 23(3): 723-32, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25179689
19.
Preferences for cancer support group topics and group satisfaction among patients and caregivers.
J Psychosoc Oncol
; 32(1): 112-23, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24428254
20.
Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL).
Support Care Cancer
; 21(1): 165-72, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22684988